ELCC 2022 | The evolution of biomarkers in NSCLC

Federico Cappuzzo, MD, PhD, Istituto Nazionale Tumori, Rome, Italy, discusses the increase in the number of biomarkers in non-small cell lung cancer (NSCLC) over recent years and the importance of next generation sequencing (NGS) technologies for the clinical management of patients, irrespective of disease stage. Although the assessment of biomarkers was initially reserved for metastatic disease, current data has highlighted the significance of biomarkers in early stage NSCLC. This interview took place during the virtual European Lung Cancer Congress 2022.